Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial-Reference-Cited by-同舟云学术

Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial

Published:2022-09 Issue:9 Volume:22 Page:e836-e843
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Stelljes Matthias^ORCID,Advani Anjali S,DeAngelo Daniel J,Wang Tao,Neuhof Alexander,Vandendries Erik,Kantarjian Hagop^ORCID,Jabbour Elias

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL);Al-Sawaf;Am J Hematol,2019

2. Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy;Emond;Clin Lymphoma Myeloma Leuk,2019

3. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia;Kujawski;Blood,2008

4. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells;Zent;Am J Hematol,2014

5. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial;Morschhauser;J Clin Oncol,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. Recommendations for the treatment and management of adult B‐Cell acute lymphoblastic leukemia in Asia‐Pacific: Outcomes from a pilot initiative;Asia-Pacific Journal of Clinical Oncology;2023-12-26